Allarity Therapeutics Signs Commercial Agreement for Breast Cancer Drug Development

Allarity Therapeutics has signed a non-exclusive global license agreement with an EU-based biotech company for its DRP algorithms in breast cancer. The deal provides the partner with access to advanced transcriptome analysis services and purchase commitments for lab services over the next year. The agreement is not expected to significantly impact Allarity's financial outlook.

Allarity Therapeutics (NASDAQ: ALLR) has entered into a strategic commercial agreement with an undisclosed EU-based biotech company, granting the latter non-exclusive global licensing rights to the company's DRP® algorithms in breast cancer. The deal, announced on July 15, 2025, also includes advanced transcriptome analysis services and purchase commitments for lab services from Allarity's Medical Laboratory in Denmark over the next year [1].

The DRP® platform, which uses gene expression profiling to predict tumor responses to specific therapies, is a cornerstone of Allarity's precision oncology efforts. The agreement represents a validation of the technology's broad applicability and potential for commercialization. However, the company emphasized that the deal is not expected to have a significant impact on its financial outlook [1].

Thomas Jensen, CEO of Allarity Therapeutics, highlighted the strategic importance of the deal. "This new agreement is an important validation of the broad applicability of our DRP® technology," he said. "Our numerous drug-specific DRPs are built on decades of research and development, and we are pleased to see this work move closer to benefiting more patients in this manner. The agreement also underscores the recognition of our laboratory’s expertise in advanced transcriptomic testing while also offsetting our internal operating costs. We look forward to supporting more partners as they develop precision oncology approaches, further expanding awareness of our DRP® platform across the industry."

The agreement is part of Allarity's broader strategy to leverage its intellectual property and expand its laboratory services. By licensing its DRP® technology, the company aims to enhance its market presence and offset internal operating costs. The fact that Allarity can monetize these assets while still focusing on its core stenoparib development program demonstrates management's effective use of intellectual property [1].

References:
[1] https://www.stocktitan.net/news/ALLR/allarity-therapeutics-announces-new-licensing-and-laboratory-d42plfasz9hx.html
[2] https://www.globenewswire.com/news-release/2025/07/15/3115497/0/en/Allarity-Therapeutics-Announces-New-Licensing-and-Laboratory-Services-Agreement-to-Expand-DRP-Platform-Utilization.html